Vimarsana
Biggest News Aggregation in the World

Page 6 - Advanced Prostate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Prostate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Prostate Today - Breaking & Trending Today

Understanding the current medical landscape of prostate cancer - Vimarsana News

Understanding the current medical landscape of prostate cancer

In this interview, News-Medical talks to Dr. Simon Chowdhury and Laetitia Guilloux about the current state of prostate cancer, it's prevalence, treatment options and its future.

Investegate |Arix Bioscience PLC Announcements | Arix Bioscience PLC: Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting - Vimarsana News

Investegate |Arix Bioscience PLC Announcements | Arix Bioscience PLC: Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting

Investegate announcements from Arix Bioscience PLC, Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting

Arix Bioscience PLC: Harpoon presents updated interim clinical data -2- - Vimarsana News

Arix Bioscience PLC: Harpoon presents updated interim clinical data -2-

DJ Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting Arix Bioscience PLC (ARIX) Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO

Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting - Vimarsana News

Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting

DJ Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting Arix Bioscience PLC (ARIX) Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO

Novartis Pharma AG: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study - Vimarsana News

Novartis Pharma AG: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Novartis Pharma AG: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study 177 Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or death (median rPFS benefit of 5 months) compared to best standard of care alone 1 Significant improvement demonstrated in all key secondary endpoints, including time to first symptomatic skeletal event,...